Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

Drug Metabolism and Disposition

Volumn 38, Issue 11, 2010, Pages 1944-1953

  Malm Erjefält, Monika ^a   Bjørnsdottir, Inga ^a   Vanggaard, Jan ^a   Helleberg, Hans ^a   Larsen, Uffe ^a   Oosterhuis, Berend ^b   Van Lier, Jan Jaap ^b   Zdravkovic, Milan ^a   Olsen, Anette K ^a  

^a NOVO NORDISK A S   (Denmark)

^b Clinical Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DRUG METABOLITE; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; MEMBRANE METALLOENDOPEPTIDASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHROMATOGRAPHY; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDYL PEPTIDASE 4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; NEPRILYSIN;

EID: 78049365082     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034066     Document Type: Article

References (34)

1. Agersø H, Jensen LB, Elbrønd B, Rolan P, and Zdravkovic M (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195-202. (Pubitemid 34208381)
2. Carone FA, Peterson DR, and Flouret G (1982) Renal tubular processing of small peptide hormones. J Lab Clin Med 100:1-14.
3. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, and Parkes DG (2006) Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7:367-374.
4. Deacon CF, Johnsen AH, and Holst JJ (1995a) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocr Metab 80:952-957.
5. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131.
6. Deacon CF, Pridal L, Klarskov L, Olesen M, and Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458-E464.
7. Edwards RM, Pullen M, and Nambi P (1999) Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology 59:45-50.
8. Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, Sturis J, Hatorp V, and Zdravkovic M (2002) Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25:1398-1404.
9. Flint A, Nazzal K, Jagielski P, Hindsberger C, and Zdravkovic M (2010) Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol doi:10.1111/j.1365-2125.2010.03762.x.
10. Foy JM (1964) The biological half-life of tritiated water in the mouse, rat, guinea-pig and rabbit under tropical conditions and the effect of climate and saline drinking on the biological half-life of tritiated water in the rat. J Cell Physiol 64:279-282.
11. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, and LEAD-3 (Mono) Study Group (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481.
12. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439.
13. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B, and Voigt K (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149-156.
14. Jacobsen LV, Hindsberger C, Robson R, and Zdravkovic M (2009) Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 68:898-905.
15. Johansen OE and Whitfield R (2008) Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 66:568-569.
16. Kettmann U, Humbel B, and Holzhausen HJ (1992) Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochem 92:225-227.
17. Knudsen LB (2004) Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 47:4128-4134. (Pubitemid 39045416)
18. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thøgersen H, Wilken M, and Agersø H (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43:1664-1669.
19. Larsen US, Hansen HB, Dahl AM, Sørensen L, and Kristensen JB (2007) Tritium labelling of the GLP-1 analogue liraglutide. J Labelled Comp Radiopharm 50:549-550.
20. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, and Lins R (2007) Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64:317-327.
21. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, and Johansen NL (2007) Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 50:6126-6132.
22. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, and Gallwitz B (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:654-662.
23. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
24. Mentlein R, Gallwitz B, and Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835. (Pubitemid 23188160)
25. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR, and LEAD-2 Study Group (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 32:84-90.
26. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, and Young A (2001) Pharmacokinetic actions of exenatide-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53:260-267.
27. Plamboeck A, Holst JJ, Carr RD, and Deacon CF (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48:1882-1890.
28. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC, and Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146. (Pubitemid 23108243)
29. Ruiz-Grande C, Alarcón C, Alcántara A, Castilla C, López Novoa JM, Villanueva-Peñacarrillo ML, and Valverde I (1993) Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25:612-616.
30. Ruiz-Grande C, Pintado J, Alarcón C, Castilla C, Valverde I, and López-Novoa JM (1990) Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol 68:1568-1573.
31. Simonsen L, Holst JJ, and Deacon CF (2006) Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 49:706-712.
32. Steensgaard DB, Thomsen JK, Olsen HB, and Knudsen LB (2008) The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide (Abstract 552-P). Diabetes 57 (Suppl 1):A164.
33. Turner AJ, Isaac RE, and Coates D (2001) The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23:261-269.
34. Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, et al. (2008) Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 25:152-156.